Theralase Technologies Inc.
TLTFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 27.3% | 141% | -77.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56.8% | 54% | 14.6% | 64.1% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $2 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -364.8% | -443.8% | -1,631.3% | -225.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -361.9% | -433.2% | -1,613.4% | -223.7% |
| EPS | -0.004 | -0.004 | -0.006 | -0.004 |
| % Growth | -5.3% | 36.7% | -57.9% | – |
| EPS Diluted | -0.004 | -0.004 | -0.006 | -0.004 |
| Weighted Avg Shares Out | 251 | 249 | 248 | 240 |
| Weighted Avg Shares Out Dil | 251 | 249 | 248 | 240 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -336.7% | -403.1% | -1,536.5% | -205.7% |